Evidence map›Paper›PMID 25057339›Full record

ReviewInternational journal of physiology, pathophysiology and pharmacology2014

Active ingredients of ginger as potential candidates in the prevention and treatment of diseases via modulation of biological activities.

Arshad H Rahmani, Fahad M Al Shabrmi, Salah M Aly

Abstract readReview
In one paragraph

Review in International journal of physiology, pathophysiology and pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The effect of ginger (Zingiber officinale Roscoe) in patients with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Trial
  3. Bioactive Compounds of Ginger (Antibiotics (Basel, Switzerland) · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Design and Evaluation of aPharmaceutics · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arshad H RahmaniDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University Saudi Arabia.
Fahad M Al ShabrmiDepartment of Radiology, College of Applied Medical Sciences, Qassim University Saudi Arabia.
Salah M AlyDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University Saudi Arabia ; Department of Pathology, Faculty of Vet. Medicine, Suez Canal University Ismailia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current mode of treatment based on synthetic drugs is expensive and also causes genetic and metabolic alterations. However, safe and sound mode of treatment is needed to control the diseases development and progression. In this regards, medicinal plant and its constituents play an important role in diseases management via modulation of biological activities. Ginger, the rhizome of the Zingiber officinale, has shown therapeutic role in the health management since ancient time and considered as potential chemopreventive agent. Numerous studies based on clinical trials and animal model has shown that ginger and its constituents shows significant role in the prevention of diseases via modulation of genetic and metabolic activities. In this review, we focused on the therapeutics effects of ginger and its constituents in the diseases management, and its impact on genetic and metabolic activities.

Indexed as

anti-microbial activityanti-tumour activityGingerneuro-protector effect

Identifiers

PMID25057339
PMCPMC4106649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.